MedTrace Logo

Study of NMS-1286937 in Adult Patients With Advanced/Metastatic Solid Tumors

NCT01014429 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2012-09-07

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and tolerability of NMS-1286937, a polo-like-kinase 1 inhibitor, in patients with advanced metastatic solid tumor.

Conditions

  • Advanced or Metastatic Solid Tumors

Interventions

DRUG

NMS-1286937

Single Arm, dose escalation study. No. of cycles: until progression or unacceptable toxicity develops.

Sponsors & Collaborators

  • Nerviano Medical Sciences

    lead INDUSTRY

Principal Investigators

  • Mariangela Mariani, Biol Sci D · Nerviano Medical Sciences

  • Maria Adele Pacciarini, Biol Sci D · Nerviano Medical Sciences

  • Glen J Weiss, MD · Arizona TGen Clinical Reserch Services at Scottsdale Healthcare

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2011-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01014429 on ClinicalTrials.gov